Morgan Stanley Keeps Their Hold Rating on Exelixis (EXEL)
Morgan Stanley analyst Sean Laaman maintained a Hold rating on Exelixis today and set a price target of $49.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Laaman covers the Healthcare sector, focusing on stocks such as Disc Medicine, Exelixis, and BridgeBio Pharma. According to TipRanks, Laaman has an average return of 10.6% and a 63.87% success rate on recommended stocks.
In addition to Morgan Stanley, Exelixis also received a Hold from RBC Capital’s Leonid Timashev in a report issued yesterday. However, today, TipRanks – Google reiterated a Buy rating on Exelixis (NASDAQ: EXEL).
Based on Exelixis’ latest earnings release for the quarter ending October 3, the company reported a quarterly revenue of $597.76 million and a net profit of $193.58 million. In comparison, last year the company earned a revenue of $539.54 million and had a net profit of $117.97 million
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Most recently, in November 2025, DAVID EDWARD JOHNSON, a Director at EXEL bought 27,532.00 shares for a total of $1,187,179.84.
Read More on EXEL:
